Patents Examined by Bridget Bunner
  • Patent number: 7378098
    Abstract: In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: May 27, 2008
    Assignees: The University of British Columbia, Chemokine Therapeutics Corporation
    Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
  • Patent number: 7312314
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: December 25, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7309777
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: December 18, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7304136
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: December 4, 2007
    Assignee: Genentech, inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7304132
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: December 4, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7282558
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: October 16, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7282208
    Abstract: The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a wound of the subject an effective amount for stimulating wound healing of a composition, wherein the composition comprises p43 having an amino acid sequence set forth in SEQ ID NO: 1 or functional equivalents thereof. The composition used in the method of the present invention can be efficiently utilized for the wound healing, since p43, an effective ingredient of the composition, has an excellent effect on the wound healing by its action including the induction of macrophage/monocyte and endothelial cell, re-epithelization, proliferation of fibroblasts or angiogenesis.
    Type: Grant
    Filed: July 22, 2003
    Date of Patent: October 16, 2007
    Assignee: aTyr Pharma, Inc.
    Inventor: Sunghoon Kim
  • Patent number: 7282201
    Abstract: This invention has as its object providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors which are useful as therapeutics of diseases that result from insufficient growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors, in particular, as therapeutics of panhematopenia and/or diseases that are accompanied by hematopoietic hypofunction. The invention attains the stated object by providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors that contain Cofilin as an active ingredient.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: October 16, 2007
    Assignee: Asubio Pharma Co., Ltd.
    Inventors: Kenju Miura, Munetada Haruyama, Shiho Kodama
  • Patent number: 7279551
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: October 9, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7267959
    Abstract: It has been found that syntaxin binds and regulates the nucleotide binding folds (NBFs) of sulfonylurea receptors (SURs) in a ATP- and ADP-dependent manner. The present invention therefore provides methods for identifying compounds that effect the binding between a syntaxin protein and a NBF1 and/or NBF2 of a sulfonylurea receptor (SUR). Compounds identified using the method of the invention are useful for treating and/or preventing diseases and/or conditions that have, as their underlying basis, a dysregulation of KAT 191 channels.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: September 11, 2007
    Inventor: Herbert Young Gaisano
  • Patent number: 7265211
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: September 4, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • Patent number: 7258864
    Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising administering insulin-like growth factor-I to a patient having a height which, at the time of treatment or prior to initial treatment with IGF-1, is at least about 2 standard deviations below normal for a subject of the same age and gender, a blood level of insulin-like growth factor-I that, and at the time of treatment or prior to initial treatment with IGF-1, is below normal mean levels, usually at least about 1 standard deviations below normal mean levels, for age and gender.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: August 21, 2007
    Assignee: Tercica, Inc.
    Inventor: Ross G. Clark
  • Patent number: 7253267
    Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: August 7, 2007
    Assignee: Bolder Biotechnology Inc.
    Inventor: George N. Cox, III
  • Patent number: 7244586
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Drosophila melanogaster ligand-gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding Drosophila ligand-gated ion channel proteins, substantially purified forms of associated Drosophila ligand-gated ion channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Drosophila melanogaster ligand-gated ion channel proteins, which will be useful as insecticides.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: July 17, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Doris F. Cully, Birgit Priest, Jeffrey Yuan, Yingcong Zheng
  • Patent number: 7244556
    Abstract: It is intended to identify and provide a novel carnitine transporter gene participating in carnitine transport in the testis and epididymis and carnitine transporter which is a protein encoded by the gene. A protein comprising the amino acid sequence represented by SEQ ID NO:2 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting carnitine or its analog; and a gene encoding this protein.
    Type: Grant
    Filed: May 27, 2002
    Date of Patent: July 17, 2007
    Assignee: Human Cell Systems, Inc.
    Inventors: Hitoshi Endou, Yoshikatsu Kanai, Atsushi Enomoto
  • Patent number: 7232893
    Abstract: The present invention provides compositions and methods for selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury. The invention describes conditioned media from immortalized hepatocytes as containing a death factor that induces apoptosis of activated liver stellate cells. This pro-apoptotic activity is shown to be associated with an 80 kDa protein, which is associated with a fetuin peptide sequence and an albumin peptide sequence.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: June 19, 2007
    Assignee: Saint Louis University
    Inventors: Ranjit Ray, Ratna Ray, Arnab Basu, Yie-Hwa Chang
  • Patent number: 7220568
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: May 22, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 7208149
    Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: April 24, 2007
    Assignee: Trustees of Boston University
    Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
  • Patent number: 7204979
    Abstract: Multipotent neural stem cell (MNSC) progeny are induced to generate cells of the hematopoietic system by placing the MNSC progeny in a hematopoietic-inducing environment. The hematopoietic-inducing environment can be either ex vivo or in vivo. A mammal's circulatory system provides an in vivo environment that can induce xenogeneic, allogeneic, or autologous MNSC progeny to generate a full complement of hematopoietic cells. Transplantation of MNSC progeny provides an alternative to bone marrow and hematopoietic stem cell transplantation to treat blood-related disorders.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: April 17, 2007
    Assignee: Neurospheres Holdings Ltd.
    Inventors: Christopher R. Bjornson, Rod L. Rietze, Brent A. Reynolds, Angelo L. Vescovi
  • Patent number: 7195879
    Abstract: The present invention provides methods to manipulate differentiation of a neuroblastoma cell line (IMR-32) such that predominant Nav expression is either Nav1.3 in IMR-32 cells exposed to retinoic acid or Nav1.7 in cells grown under non-differentiating conditions. The cells of the present invention are useful for the discovery of new compounds that modulate the function of either Nav1.3 and/or Nav1.7.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: March 27, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Adrienne Dubin, Sandra Chaplan, Sean Brown, Edward Kaftan